Epidemiological Characteristics of Meningococcal Meningitis (2016 to 2018) Four Years after the Introduction of Serogroup A Meningococcal Conjugate Vaccine in Benin

被引:1
|
作者
Godjedo, Togbemabou Primous Martial [1 ,2 ]
Agbankpe, Alidehou Jerrold [3 ]
Paraiso, Moussiliou Noel [4 ]
Dougnon, Tamegnon Victorien [3 ]
Hidjo, Marie [3 ]
Baba-Moussa, Lamine [5 ]
Bankole, Honore [1 ,3 ]
机构
[1] Minist Publ Hlth, Epidmiol Surveillance Serv, Cotonou, Benin
[2] Minist Publ Hlth, Natl Hlth Lab, Cotonou, Benin
[3] Univ Abomey Calavi, Res Lab Appl Biol, Polytech Sch Abomey Calavi, Res Unit Appl Microbiol & Pharmacol Nat Subst, Cotonou, Benin
[4] Univ Abomey Calavi, Reg Inst Publ Hlth, Cotonou, Benin
[5] Univ Abomey Calavi, Lab Biol & Mol Typing Microbiol, Fac Sci & Technol, Cotonou, Benin
来源
ADVANCES IN PUBLIC HEALTH | 2020年 / 2020卷
关键词
BACTERIAL-MENINGITIS; COUNTRIES; BELT; SURVEILLANCE; AFRICA;
D O I
10.1155/2020/1932940
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objectives. This study aims to study the epidemiological and geographic characteristics of the meningococcal serogroups four years after the introduction of serogroup A meningococcal conjugate vaccine.Methods. This is a prospective, descriptive, analytical study, and it took place from 2016 to 2018. Cerebrospinal fluid (CSF) samples were taken after the identification of meningitis cases. The samples, thus, taken were sent to the laboratory for culture and identification ofNeisseria meningitidisin accordance with WHO standards.Results. Eight hundred and ninety-nine bacterial strains were identified, of which 219 were strains ofNeisseria meningitidis. The majority ofN. meningitidis-positive samples were from male patients (59.8%) with a median age of 4 (IQR: 1-13). Four ofN. meningitidisserogroups were identified, namely, serogroups C (6.8%), W (19.6%), X (1.8%), and A (0.5%). Geographically, 92.7% of the identifiedN. meningitidisserogroups came from patients who lived in the northern region of the country. The departments most concerned were Alibori (N. meningitidisC (66.7%) andN. meningitidisW (20.9%)); Atacora (N. meningitidisW (41.9%),N. meningitidisX (75.0%), andN. meningitidisC (13.3%)); and Borgou (N. meningitidisW (23.3%)).Conclusion. The results of this study showed that there is an emergence of cases of meningococcal of serogroup C four years after the introduction of MenAfricVac in Benin. These results demonstrated the effectiveness of case-by-case surveillance in detecting small changes in the distribution of serogroups that could have important implications for public health strategies in the coming seasons.
引用
收藏
页数:7
相关论文
共 22 条
  • [1] Meningococcal Meningitis Outbreaks in the African Meningitis Belt After Meningococcal Serogroup A Conjugate Vaccine Introduction, 2011-2017
    Fernandez, Katya
    Lingani, Clement
    Aderinola, Olaolu Moses
    Goumbi, Kadade
    Bicaba, Brice
    Edea, Zewdu Assefa
    Glele, Clement
    Sarkodie, Badu
    Tamekloe, Agbeko
    Ngomba, Armelle
    Djingarey, Mamoudou
    Bwaka, Ado
    Perea, William
    Ronveaux, Olivier
    JOURNAL OF INFECTIOUS DISEASES, 2019, 220 : S225 - S232
  • [2] Epidemiology of Bacterial Meningitis in the Nine Years Since Meningococcal Serogroup A Conjugate Vaccine Introduction, Niger, 2010-2018
    Sidikou, Fati
    Potts, Caelin C.
    Zaneidou, Maman
    Mbaeyi, Sarah
    Kadade, Goumbi
    Paye, Marietou F.
    Ousmane, Sani
    Issaka, Bassira
    Chen, Alexander
    Chang, How-Yi
    Issifou, Djibo
    Lingani, Clement
    Sakande, Souleymane
    Bienvenu, Baruani
    Mahamane, Ali Elhadji
    Diallo, Alpha Oumar
    Moussa, Amadou
    Seidou, Issaka
    Abdou, Moussa
    Sidiki, Ali
    Garba, Omar
    Haladou, Sani
    Testa, Jean
    Nse, Ricardo Obama
    Mainassara, Halima Boubacar
    Wang, Xin
    JOURNAL OF INFECTIOUS DISEASES, 2019, 220 : S206 - S215
  • [3] Molecular insights into meningococcal carriage isolates from Burkina Faso 7 years after introduction of a serogroup A meningococcal conjugate vaccine
    Topaz, Nadav
    Kristiansen, Paul Arne
    Schmink, Susanna
    Congo-Ouedraogo, Malika
    Kambire, Dinanibe
    Mbaeyi, Sarah
    Paye, Marietou
    Sanou, Mahamoudou
    Sangare, Lassana
    Ouedraogo, Rasmata
    Wang, Xin
    MICROBIAL GENOMICS, 2020, 6 (12): : 1 - 9
  • [4] Meningococcal carriage 7 years after introduction of a serogroup A meningococcal conjugate vaccine in Burkina Faso: results from four cross-sectional carriage surveys
    Mbaeyi, Sarah
    Sampo, Emmanuel
    Dinanibe, Kambire
    Yameogo, Issaka
    Congo-Ouedraogo, Malika
    Tamboura, Mamadou
    Sawadogo, Guetawende
    Ouattara, Kalifa
    Sanou, Mahamadou
    Kiemtore, Tanga
    Dioma, Gerard
    Sanon, Barnabe
    Somlare, Hermann
    Kyetega, Augustin
    Ba, Absatou Ky
    Ake, Flavien
    Tarbangdo, Felix
    Aboua, Frederic Acho
    Donnou, Yvette
    Kamate, Idrissa
    Patel, Jaymia C.
    Schrilink, Susanna
    Spiller, Michael W.
    Topaz, Nadav
    Novak, Ryan
    Wang, Xin
    Bicaba, Brice
    Sangare, Lassana
    Ouedraogo-Traore, Rosmata
    Kristiansen, Paul A.
    LANCET INFECTIOUS DISEASES, 2020, 20 (12) : 1418 - 1425
  • [5] Microbiological and epidemiological investigation of the Neisseria meningitidis serogroup A epidemic in Niger in 2009: last wave before the introduction of the serogroup A meningococcal conjugate vaccine?
    Collard, J. M.
    Maman, Z.
    Abani, A.
    Mainasara, H. B.
    Djibo, S.
    Yacouba, H.
    Maitournam, R.
    Sidikou, F.
    Nicolas, P.
    Rocourt, J.
    Jusot, J. F.
    EPIDEMIOLOGY AND INFECTION, 2011, 139 (11) : 1656 - 1660
  • [6] Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac
    Kristiansen, Paul A.
    Ba, Absatou Ky
    Ouedraogo, Abdoul-Salam
    Sanou, Idrissa
    Ouedraogo, Rasmata
    Sangare, Lassana
    Diomande, Fabien
    Kandolo, Denis
    Saga, Inger Marie
    Misegades, Lara
    Clark, Thomas A.
    Preziosi, Marie-Pierre
    Caugant, Dominique A.
    BMC INFECTIOUS DISEASES, 2014, 14
  • [7] A Decade of Herd Protection After Introduction of Meningococcal Serogroup C Conjugate Vaccination
    Bijlsma, Merijn W.
    Brouwer, Matthijs C.
    Spanjaard, Lodewijk
    van de Beek, Diederik
    van der Ende, Arie
    CLINICAL INFECTIOUS DISEASES, 2014, 59 (09) : 1216 - 1221
  • [8] Vaccination information, motivations, and barriers in the context of meningococcal serogroup A conjugate vaccine introduction: A qualitative assessment among caregivers in Burkina Faso, 2018
    Aksnes, Brooke Noel
    Walldorf, Jenny A.
    Nkwenkeu, Sylvain F.
    Zoma, Robert L.
    Mirza, Imran
    Tarbangdo, Felix
    Fall, Soukeynatou
    Hien, Sansan
    Ky, Cesaire
    Kambou, Ludovic
    Diallo, Alpha Oumar
    Ake, Flavien H.
    Hatcher, Cynthia
    Patel, Jaymin C.
    Novak, Ryan T.
    Hyde, Terri B.
    Medah, Isaie
    Soeters, Heidi M.
    Jalloh, Mohamed F.
    VACCINE, 2021, 39 (43) : 6370 - 6377
  • [9] Kinetics of Meningococcal Serogroup C-Specific Functional Antibody Levels Up to 15 Years after a Single Immunization with a Meningococcal Serogroup C Conjugate Vaccine during Adolescence
    Stoof, Susanne P.
    van Ravenhorst, Mariette B.
    van Rooijen, Debbie M.
    de Voer, Richarda M.
    van der Klis, Fiona R. M.
    Boland, Greet J.
    Sanders, Elisabeth A. M.
    Berbers, Guy A. M.
    Teunis, Peter F.
    CLINICAL AND VACCINE IMMUNOLOGY, 2017, 24 (02)
  • [10] Changing epidemiology of Infant Meningococcal Disease after the introduction of meningococcal serogroup C vaccine in Italy, 2006-2014
    Stefanelli, P.
    Fazio, C.
    Neri, A.
    Boros, S.
    Renna, G.
    Pompa, M. G.
    VACCINE, 2015, 33 (31) : 3678 - 3681